Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty

International Journal of Cardiology

Volumn 127, Issue 2, 2008, Pages 284-287

  Samimi Fard, Sima ^a   García González, Martín J ^a   Domínguez Rodríguez, Alberto ^a   Abreu González, Pedro ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Cardiogenic shock; Dobutamine; Levosimendan; Long term survival

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY HEMODYNAMICS; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOTONIC AGENTS; DOBUTAMINE; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PYRIDAZINES; SHOCK, CARDIOGENIC; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 44649131858     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.143     Document Type: Article

References (11)

1. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock?. N Engl J Med 341 (1999) 625-634
2. Carnendran L., Abboud R., Sleeper L.A., et al. Trends in cardiogenic shock: report from the SHOCK Study. The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. Eur Heart J 22 (2001) 472-478
3. Perrone S.V., and Kaplinsky E.J. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 103 (2005) 248-255
4. Nieminen M.S., Bohm M., Cowie M.R., et al. ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
5. García-González M.J., Domínguez-Rodríguez A., Ferrer-Hita J.J., Abreu-Gonzalez P., and Bethencourt-Muñoz M. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 8 (2006) 723-728
6. Granger C.B., Goldberg R.J., Dabbous O., et al. Global registry of acute coronary events investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
7. Delle Karth G., Buberl A., Geppert A., et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47 (2003) 1251-1256
8. Lehmann A., Lang J., Boldt J., Isgro F., and Kiessling A.H. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 10 (2004) 89-93
9. García-González M.J., Domínguez-Rodríguez A., and Ferrer-Hita J.J. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 45 (2005) 704-708
10. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
11. Cleland J.G.F., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110